癌モノクローナル抗体の提携条件・合意の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-15002 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、125ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、癌モノクローナル抗体の提携条件・合意の世界市場を広く調査・分析し、今後の市場展望をまとめております。癌モノクローナル抗体の提携条件・合意の種類別市場規模（資産購入、共同研究開発、合弁事業、ライセンス供与、その他）、用途別市場規模（製薬産業、バイオテクノロジー、医療、教育・研究、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：3SBio、Ascension、Abzena、4D Pharma、Agenus Bio、Abbvie、Aslan Pharma、Aeglea BioTherapeutics、Adaptive Biotechnologies、Ascentage Pharma、Bayer、Chiome Bioscience、Telix Pharmaceuticals、Cantargia、Baxalta、Basilea Pharmaceutica、Clovis Oncology、Apollomics、Bavarian Nordic ・地域別グローバル市場分析 2015年-2020年 ・癌モノクローナル抗体の提携条件・合意の北米市場（アメリカ、カナダ、メキシコ） ・癌モノクローナル抗体の提携条件・合意のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・癌モノクローナル抗体の提携条件・合意のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・癌モノクローナル抗体の提携条件・合意の南米市場（ブラジル、アルゼンチン） ・癌モノクローナル抗体の提携条件・合意の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：資産購入、共同研究開発、合弁事業、ライセンス供与、その他 ・用途別分析：製薬産業、バイオテクノロジー、医療、教育・研究、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Cancer Monoclonal Antibody Partnering Terms and Agreements market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Cancer Monoclonal Antibody Partnering Terms and Agreements market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Cancer Monoclonal Antibody Partnering Terms and Agreements market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Cancer Monoclonal Antibody Partnering Terms and Agreements market has been segmented into:
Asset Purchase
Collaborative R&D
Joint Venture
Licensing
Other

By Application, Cancer Monoclonal Antibody Partnering Terms and Agreements has been segmented into:
Pharmaceutical Industry
Biotechnology
Medical Care
Education and Research
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Cancer Monoclonal Antibody Partnering Terms and Agreements market presented in the report. This section sheds light on the sales growth of different regional and country-level Cancer Monoclonal Antibody Partnering Terms and Agreements markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Cancer Monoclonal Antibody Partnering Terms and Agreements market.

The report offers in-depth assessment of the growth and other aspects of the Cancer Monoclonal Antibody Partnering Terms and Agreements market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share Analysis
Cancer Monoclonal Antibody Partnering Terms and Agreements competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Cancer Monoclonal Antibody Partnering Terms and Agreements sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Cancer Monoclonal Antibody Partnering Terms and Agreements sales, revenue and market share for each player covered in this report.

The major players covered in Cancer Monoclonal Antibody Partnering Terms and Agreements are:
3SBio
Ascension
Abzena
4D Pharma
Agenus Bio
Abbvie
Aslan Pharma
Aeglea BioTherapeutics
Adaptive Biotechnologies
Ascentage Pharma
Bayer
Chiome Bioscience
Telix Pharmaceuticals
Cantargia
Baxalta
Basilea Pharmaceutica
Clovis Oncology
Apollomics
Bavarian Nordic

レポート目次

---

Table of Contents

1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Overview
1.1 Product Overview and Scope of Cancer Monoclonal Antibody Partnering Terms and Agreements
1.2 Classification of Cancer Monoclonal Antibody Partnering Terms and Agreements by Type
1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type in 2019
1.2.3 Asset Purchase
1.2.4 Collaborative R&D
1.2.5 Joint Venture
1.2.6 Licensing
1.2.7 Other
1.3 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market by Application
1.3.1 Overview: Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Medical Care
1.3.5 Education and Research
1.3.6 Other
1.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market by Regions
1.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Cancer Monoclonal Antibody Partnering Terms and Agreements (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Cancer Monoclonal Antibody Partnering Terms and Agreements Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Cancer Monoclonal Antibody Partnering Terms and Agreements Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cancer Monoclonal Antibody Partnering Terms and Agreements Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Cancer Monoclonal Antibody Partnering Terms and Agreements Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cancer Monoclonal Antibody Partnering Terms and Agreements Status and Prospect (2015-2025)
2 Company Profiles
2.1 3SBio
2.1.1 3SBio Details
2.1.2 3SBio Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 3SBio SWOT Analysis
2.1.4 3SBio Product and Services
2.1.5 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.2 Ascension
2.2.1 Ascension Details
2.2.2 Ascension Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Ascension SWOT Analysis
2.2.4 Ascension Product and Services
2.2.5 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.3 Abzena
2.3.1 Abzena Details
2.3.2 Abzena Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Abzena SWOT Analysis
2.3.4 Abzena Product and Services
2.3.5 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.4 4D Pharma
2.4.1 4D Pharma Details
2.4.2 4D Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 4D Pharma SWOT Analysis
2.4.4 4D Pharma Product and Services
2.4.5 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.5 Agenus Bio
2.5.1 Agenus Bio Details
2.5.2 Agenus Bio Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Agenus Bio SWOT Analysis
2.5.4 Agenus Bio Product and Services
2.5.5 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.6 Abbvie
2.6.1 Abbvie Details
2.6.2 Abbvie Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Abbvie SWOT Analysis
2.6.4 Abbvie Product and Services
2.6.5 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.7 Aslan Pharma
2.7.1 Aslan Pharma Details
2.7.2 Aslan Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Aslan Pharma SWOT Analysis
2.7.4 Aslan Pharma Product and Services
2.7.5 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.8 Aeglea BioTherapeutics
2.8.1 Aeglea BioTherapeutics Details
2.8.2 Aeglea BioTherapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Aeglea BioTherapeutics SWOT Analysis
2.8.4 Aeglea BioTherapeutics Product and Services
2.8.5 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.9 Adaptive Biotechnologies
2.9.1 Adaptive Biotechnologies Details
2.9.2 Adaptive Biotechnologies Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Adaptive Biotechnologies SWOT Analysis
2.9.4 Adaptive Biotechnologies Product and Services
2.9.5 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.10 Ascentage Pharma
2.10.1 Ascentage Pharma Details
2.10.2 Ascentage Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Ascentage Pharma SWOT Analysis
2.10.4 Ascentage Pharma Product and Services
2.10.5 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.11 Bayer
2.11.1 Bayer Details
2.11.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Bayer SWOT Analysis
2.11.4 Bayer Product and Services
2.11.5 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.12 Chiome Bioscience
2.12.1 Chiome Bioscience Details
2.12.2 Chiome Bioscience Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Chiome Bioscience SWOT Analysis
2.12.4 Chiome Bioscience Product and Services
2.12.5 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.13 Telix Pharmaceuticals
2.13.1 Telix Pharmaceuticals Details
2.13.2 Telix Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Telix Pharmaceuticals SWOT Analysis
2.13.4 Telix Pharmaceuticals Product and Services
2.13.5 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.14 Cantargia
2.14.1 Cantargia Details
2.14.2 Cantargia Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Cantargia SWOT Analysis
2.14.4 Cantargia Product and Services
2.14.5 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.15 Baxalta
2.15.1 Baxalta Details
2.15.2 Baxalta Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Baxalta SWOT Analysis
2.15.4 Baxalta Product and Services
2.15.5 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.16 Basilea Pharmaceutica
2.16.1 Basilea Pharmaceutica Details
2.16.2 Basilea Pharmaceutica Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Basilea Pharmaceutica SWOT Analysis
2.16.4 Basilea Pharmaceutica Product and Services
2.16.5 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.17 Clovis Oncology
2.17.1 Clovis Oncology Details
2.17.2 Clovis Oncology Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Clovis Oncology SWOT Analysis
2.17.4 Clovis Oncology Product and Services
2.17.5 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.18 Apollomics
2.18.1 Apollomics Details
2.18.2 Apollomics Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Apollomics SWOT Analysis
2.18.4 Apollomics Product and Services
2.18.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
2.19 Bavarian Nordic
2.19.1 Bavarian Nordic Details
2.19.2 Bavarian Nordic Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Bavarian Nordic SWOT Analysis
2.19.4 Bavarian Nordic Product and Services
2.19.5 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Cancer Monoclonal Antibody Partnering Terms and Agreements Players Market Share
3.2.2 Top 10 Cancer Monoclonal Antibody Partnering Terms and Agreements Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Market Share by Regions
4.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
4.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
4.5 South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
5 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries
5.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
5.2 USA Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
5.3 Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
5.4 Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
6 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries
6.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
6.2 Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
6.3 UK Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
6.4 France Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
6.5 Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
6.6 Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries
7.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
7.2 China Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
7.3 Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
7.4 Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
7.5 India Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
8 South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries
8.1 South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
8.2 Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
8.3 Argentina Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Cancer Monoclonal Antibody Partnering Terms and Agreements by Countries
9.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
9.2 Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
9.3 UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
9.4 Egypt Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
9.5 South Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Market Share by Type (2015-2020)
10.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast by Type (2019-2024)
10.3 Asset Purchase Revenue Growth Rate (2015-2025)
10.4 Collaborative R&D Revenue Growth Rate (2015-2025)
10.5 Joint Venture Revenue Growth Rate (2015-2025)
10.6 Licensing Revenue Growth Rate (2015-2025)
10.7 Other Revenue Growth Rate (2015-2025)
11 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment by Application
11.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2015-2020)
11.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast by Application (2019-2024)
11.3 Pharmaceutical Industry Revenue Growth (2015-2020)
11.4 Biotechnology Revenue Growth (2015-2020)
11.5 Medical Care Revenue Growth (2015-2020)
11.6 Education and Research Revenue Growth (2015-2020)
11.7 Other Revenue Growth (2015-2020)
12 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Forecast (2021-2025)
12.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Forecast (2021-2025)
12.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Forecast by Regions (2021-2025)
12.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
12.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
12.6 South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Cancer Monoclonal Antibody Partnering Terms and Agreements by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. 3SBio Corporate Information, Location and Competitors
Table 6. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 7. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 8. 3SBio SWOT Analysis
Table 9. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 10. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Ascension Corporate Information, Location and Competitors
Table 12. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 13. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2018-2019)
Table 14. Ascension SWOT Analysis
Table 15. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 16. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Abzena Corporate Information, Location and Competitors
Table 18. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 19. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 20. Abzena SWOT Analysis
Table 21. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 22. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. 4D Pharma Corporate Information, Location and Competitors
Table 24. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 25. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 26. 4D Pharma SWOT Analysis
Table 27. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 28. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Agenus Bio Corporate Information, Location and Competitors
Table 30. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 31. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 32. Agenus Bio SWOT Analysis
Table 33. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 34. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Abbvie Corporate Information, Location and Competitors
Table 36. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 37. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 38. Abbvie SWOT Analysis
Table 39. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 40. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Aslan Pharma Corporate Information, Location and Competitors
Table 42. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 43. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 44. Aslan Pharma SWOT Analysis
Table 45. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 46. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Aeglea BioTherapeutics Corporate Information, Location and Competitors
Table 48. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 49. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 50. Aeglea BioTherapeutics SWOT Analysis
Table 51. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 52. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Adaptive Biotechnologies Corporate Information, Location and Competitors
Table 54. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 55. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 56. Adaptive Biotechnologies SWOT Analysis
Table 57. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 58. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Ascentage Pharma Corporate Information, Location and Competitors
Table 60. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 61. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 62. Ascentage Pharma SWOT Analysis
Table 63. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 64. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Bayer Corporate Information, Location and Competitors
Table 66. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 67. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 68. Bayer SWOT Analysis
Table 69. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 70. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Chiome Bioscience Corporate Information, Location and Competitors
Table 72. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 73. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 74. Chiome Bioscience SWOT Analysis
Table 75. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 76. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Telix Pharmaceuticals Corporate Information, Location and Competitors
Table 78. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 79. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 80. Telix Pharmaceuticals SWOT Analysis
Table 81. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 82. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Cantargia Corporate Information, Location and Competitors
Table 84. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 85. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 86. Cantargia SWOT Analysis
Table 87. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 88. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Baxalta Corporate Information, Location and Competitors
Table 90. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 91. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 92. Baxalta SWOT Analysis
Table 93. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 94. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Basilea Pharmaceutica Corporate Information, Location and Competitors
Table 96. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 97. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 98. Basilea Pharmaceutica SWOT Analysis
Table 99. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 100. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Clovis Oncology Corporate Information, Location and Competitors
Table 102. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 103. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 104. Clovis Oncology SWOT Analysis
Table 105. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 106. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Type and Application
Table 108. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 109. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 110. Apollomics SWOT Analysis
Table 111. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 112. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Bavarian Nordic Corporate Information, Location and Competitors
Table 114. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Major Business
Table 115. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Total Revenue (USD Million) (2017-2018)
Table 116. Bavarian Nordic SWOT Analysis
Table 117. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product and Solutions
Table 118. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Players (2015-2020)
Table 120. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Players (2015-2020)
Table 121. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Regions (2015-2020)
Table 122. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Regions (2015-2020)
Table 123. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
Table 124. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Table 125. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Countries (2015-2020)
Table 126. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Countries (2015-2020)
Table 127. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Countries (2015-2020)
Table 128. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Table 129. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Countries (2015-2020)
Table 130. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Table 131. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) by Type (2015-2020)
Table 132. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Type (2015-2020)
Table 133. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Forecast by Type (2021-2025)
Table 134. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Application (2015-2020)
Table 135. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2015-2020)
Table 136. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Forecast by Application (2021-2025)
Table 137. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Picture
Figure 2. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type in 2019
Figure 3. Asset Purchase Picture
Figure 4. Collaborative R&D Picture
Figure 5. Joint Venture Picture
Figure 6. Licensing Picture
Figure 7. Other Picture
Figure 8. Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application in 2019
Figure 9. Pharmaceutical Industry Picture
Figure 10. Biotechnology Picture
Figure 11. Medical Care Picture
Figure 12. Education and Research Picture
Figure 13. Other Picture
Figure 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share in 2019
Figure 23. Global Top 10 Players Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Regions (2015-2020)
Figure 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Regions in 2018
Figure 28. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 29. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 31. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 33. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Figure 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries in 2019
Figure 35. USA Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 36. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 38. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries in 2019
Figure 40. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 41. UK Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 42. France Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 43. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 44. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries in 2019
Figure 47. China Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 48. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 49. Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 50. India Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 52. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Figure 53. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries in 2019
Figure 54. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 59. UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue and Growth Rate (2015-2020)
Figure 62. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Type (2015-2020)
Figure 63. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Type in 2019
Figure 64. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share Forecast by Type (2021-2025)
Figure 65. Global Asset Purchase Revenue Growth Rate (2015-2020)
Figure 66. Global Collaborative R&D Revenue Growth Rate (2015-2020)
Figure 67. Global Joint Venture Revenue Growth Rate (2015-2020)
Figure 68. Global Licensing Revenue Growth Rate (2015-2020)
Figure 69. Global Other Revenue Growth Rate (2015-2020)
Figure 70. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2015-2020)
Figure 71. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application in 2019
Figure 72. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share Forecast by Application (2021-2025)
Figure 73. Global Pharmaceutical Industry Revenue Growth Rate (2015-2020)
Figure 74. Global Biotechnology Revenue Growth Rate (2015-2020)
Figure 75. Global Medical Care Revenue Growth Rate (2015-2020)
Figure 76. Global Education and Research Revenue Growth Rate (2015-2020)
Figure 77. Global Other Revenue Growth Rate (2015-2020)
Figure 78. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
Figure 82. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
Figure 84. South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel

---